Kitano S - Search Results

1

Tremelimumab-associated tumor regression following after initial progression: two case reports.

Shimomura A, Fujiwara Y, Kondo S, Kodaira M, Iwasa S, Kitano S, Tanabe Y, Tamura K, Yamamoto N. Shimomura A, et al. Among authors: kitano s. Immunotherapy. 2016;8(1):9-15. doi: 10.2217/imt.15.89. Epub 2015 Oct 2. Immunotherapy. 2016. PMID: 26427600

2

Clinical Development of Immune Checkpoint Inhibitors.

Ito A, Kondo S, Tada K, Kitano S. Ito A, et al. Among authors: kitano s. Biomed Res Int. 2015;2015:605478. doi: 10.1155/2015/605478. Epub 2015 Jun 16. Biomed Res Int. 2015. PMID: 26161407 Free PMC article. Review.

3

A novel method for evaluating antibody-dependent cell-mediated cytotoxicity by flowcytometry using cryopreserved human peripheral blood mononuclear cells.

Yamashita M, Kitano S, Aikawa H, Kuchiba A, Hayashi M, Yamamoto N, Tamura K, Hamada A. Yamashita M, et al. Among authors: kitano s. Sci Rep. 2016 Jan 27;6:19772. doi: 10.1038/srep19772. Sci Rep. 2016. PMID: 26813960 Free PMC article.

4

Pretreatment Immune Status Correlates with Progression-Free Survival in Chemotherapy-Treated Metastatic Colorectal Cancer Patients.

Tada K, Kitano S, Shoji H, Nishimura T, Shimada Y, Nagashima K, Aoki K, Hiraoka N, Honma Y, Iwasa S, Okita N, Takashima A, Kato K, Yamada Y, Katayama N, Boku N, Heike Y, Hamaguchi T. Tada K, et al. Among authors: kitano s. Cancer Immunol Res. 2016 Jul;4(7):592-9. doi: 10.1158/2326-6066.CIR-15-0298. Epub 2016 Apr 28. Cancer Immunol Res. 2016. PMID: 27197061

5

Phase 1 study of abemaciclib, an inhibitor of CDK 4 and 6, as a single agent for Japanese patients with advanced cancer.

Fujiwara Y, Tamura K, Kondo S, Tanabe Y, Iwasa S, Shimomura A, Kitano S, Ogasawara K, Turner PK, Mori J, Asou H, Chan EM, Yamamoto N. Fujiwara Y, et al. Among authors: kitano s. Cancer Chemother Pharmacol. 2016 Aug;78(2):281-8. doi: 10.1007/s00280-016-3085-8. Epub 2016 Jun 16. Cancer Chemother Pharmacol. 2016. PMID: 27312735 Clinical Trial.

6

Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy.

Nakamura Y, Kitano S, Takahashi A, Tsutsumida A, Namikawa K, Tanese K, Abe T, Funakoshi T, Yamamoto N, Amagai M, Yamazaki N. Nakamura Y, et al. Among authors: kitano s. Oncotarget. 2016 Nov 22;7(47):77404-77415. doi: 10.18632/oncotarget.12677. Oncotarget. 2016. PMID: 27764805 Free PMC article.

7

Do all patients in the phase I oncology trials need to be hospitalized? Domestic but outstanding issues for globalization of drug development in Japan.

Shimomura A, Kondo S, Kobayashi N, Iwasa S, Kitano S, Tamura K, Fujiwara Y, Yamamoto N. Shimomura A, et al. Among authors: kitano s. Int J Clin Oncol. 2017 Aug;22(4):780-785. doi: 10.1007/s10147-017-1108-z. Epub 2017 Mar 14. Int J Clin Oncol. 2017. PMID: 28293794 Free PMC article. Clinical Trial.

8

[Development of immune checkpoint inhibitors].

Kitano S. Kitano S. Rinsho Ketsueki. 2017;58(8):966-976. doi: 10.11406/rinketsu.58.966. Rinsho Ketsueki. 2017. PMID: 28883282 Japanese.

9

[Combination Therapy of Immune Checkpoint Inhibitors].

Kitano S. Kitano S. Gan To Kagaku Ryoho. 2017 Sep;44(9):727-732. Gan To Kagaku Ryoho. 2017. PMID: 28912397 Japanese.

10

Serial pseudoprogression of metastatic malignant melanoma in a patient treated with nivolumab: a case report.

Ozaki Y, Shindoh J, Miura Y, Nakajima H, Oki R, Uchiyama M, Masuda J, Kinowaki K, Kondoh C, Tanabe Y, Tanaka T, Haruta S, Ueno M, Kitano S, Fujii T, Udagawa H, Takano T. Ozaki Y, et al. Among authors: kitano s. BMC Cancer. 2017 Nov 21;17(1):778. doi: 10.1186/s12885-017-3785-4. BMC Cancer. 2017. PMID: 29162045 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,210 results

Search Page

Filters